Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial.

Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol. 2009 Aug 10; 27(23):3842-8.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Antimetabolites, Antineoplastic
Azacitidine
Drug Administration Schedule
Female
Humans
Infusions, Intravenous
Kaplan-Meier Estimate
Male
Middle Aged
Myelodysplastic Syndromes
Outpatients
Treatment Outcome

authors with profiles

Lucy Godley